Developing a novel, blood-based test for enhancing cardiac catheterization rule in/rule out
In the U.S. alone, more than 6 million patients enter the Emergency Room (ER) with complaints about chest pain every year. ER physicians and cardiologists have tests to diagnose patients who have already had a heart attack. However, often times these tests are inconclusive about heart blockage and many patients experience chest pain due to non-cardiac reasons, including heartburn, esophageal reflux, and other non-life threatening conditions. Unfortunately, a significant number of these patients receive expensive and dangerous procedures, including cardiac catheterizations ("caths") and coronary CT scans, they do not actually need.
Update: Research paper on Prevencio's biomarker technology published in BioMed Medicine.
Prevencio® is the registered trademark of Prevencio, Inc., a Delaware Corporation. Copyright (2013). All rights reserved. Diagnostic products described here are not for sale and have not been cleared by the FDA for commercial sale.
Prevencio is developing a blood biomarker test, (HART™), to assist ER physicians and cardiologists in differentiating chest pain patients who benefit from further testing from those who will not benefit from further ER medical treatment.